Vanguard vs. Big Pharma: Research Focus & Recruitment
Explore how Vanguard companies, innovative small pharma entities, differ in research focus and recruitment dynamics from larger Pharma.
Sep
2023
Jul
2023
eyesON | Phase II Vanguards
Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
Jul
2023
Enhancing Clinical Trial Risk Management: A Response to the Growing Concerns over Fraudulent Studies
In this blog, we explore the growing concerns about fraudulent RCTs highlighted in a recent Nature article. Discover how innovative risk management approaches can detect, prevent, and tackle these issues, facilitating more robust regulatory oversight.
Jun
2023
Empowering Clinical Trials: MyRBQM Portal Debuts on Microsoft Azure Marketplace
MyRBQM Portal has made its debut on the Azure Marketplace. This milestone allows biopharmaceutical companies to streamline and unify their approach to risk management by using the secure and reliable Azure cloud platform.
Jun
2023
The Technology Surrounding Decentralized Clinical Trials
How heavily do decentralized clinical trials rely on technology? We asked Craig Lipset, a leading expert in the field of decentralized clinical trials.
Jun
2023
Boosting Oncology Care with Decentralized Clinical Trials
Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.
May
2023
eyesON | Decentralized Clinical Trials Outlook: USA
Data visualization tool designed to identify untapped opportunities for Decentralized Clinical Trials advancement in the oncology sector in the USA.
May
2023
Training Implications of the ICH E6(R3) and E8(R1) Guidelines
Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.
May
2023
A Comparative Review of the ICH E6(R3) and E8(R1) Guidelines
Unpacking the new ICH guidelines, E6(R3) and E8(R1), we illuminate their key elements, identify gaps, and compare the two in terms of their unity, differences, and complementarity.
May
2023
Embracing the Future: FDA’s New Draft Guidance on Decentralized Clinical Trials
Dive into the FDA's latest draft guidance on Decentralized Clinical Trials and the role of Risk-Based Quality Management. Learn how RBQM and centralized monitoring can elevate your clinical research efficiency and reliability.